- Home
- TLSA vs SGHT Comparison
TLSA vs SGHT Comparison
Compare TLSA & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- SGHT
- Stock Information
- Founded
- TLSA 2013
- SGHT 2011
- Country
- TLSA United Kingdom
- SGHT United States
- Employees
- TLSA 9
- SGHT N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- SGHT Medical Specialities
- Sector
- TLSA Health Care
- SGHT Health Care
- Exchange
- TLSA Nasdaq
- SGHT Nasdaq
- Market Cap
- TLSA 196.1M
- SGHT 193.2M
- IPO Year
- TLSA 2000
- SGHT 2021
- Fundamental
- Price
- TLSA $1.70
- SGHT $7.17
- Analyst Decision
- TLSA
- SGHT Buy
- Analyst Count
- TLSA 0
- SGHT 8
- Target Price
- TLSA N/A
- SGHT $4.93
- AVG Volume (30 Days)
- TLSA 226.1K
- SGHT 247.0K
- Earning Date
- TLSA 01-01-0001
- SGHT 11-06-2025
- Dividend Yield
- TLSA N/A
- SGHT N/A
- EPS Growth
- TLSA N/A
- SGHT N/A
- EPS
- TLSA N/A
- SGHT N/A
- Revenue
- TLSA N/A
- SGHT $76,052,000.00
- Revenue This Year
- TLSA N/A
- SGHT N/A
- Revenue Next Year
- TLSA N/A
- SGHT $12.04
- P/E Ratio
- TLSA N/A
- SGHT N/A
- Revenue Growth
- TLSA N/A
- SGHT N/A
- 52 Week Low
- TLSA $0.63
- SGHT $2.03
- 52 Week High
- TLSA $2.60
- SGHT $8.06
- Technical
- Relative Strength Index (RSI)
- TLSA 40.73
- SGHT 74.25
- Support Level
- TLSA $1.60
- SGHT $4.86
- Resistance Level
- TLSA $1.81
- SGHT $8.06
- Average True Range (ATR)
- TLSA 0.13
- SGHT 0.43
- MACD
- TLSA -0.02
- SGHT 0.19
- Stochastic Oscillator
- TLSA 23.40
- SGHT 70.31
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.